Man Ada, Pickles Tom, Chi Kim N
Department of Radiation and Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6.
J Urol. 2003 Sep;170(3):901-4. doi: 10.1097/01.ju.0000081423.37043.b4.
We compared survival outcomes in patients of Asian descent treated with curative intent radiation therapy for prostate cancer with that in the nonAsian population in British Columbia, Canada.
Since 1994, 1,872 men treated with curative intent radiotherapy for prostate cancer have been followed prospectively at our provincial institution, where cancer care delivery is coordinated for the province of British Columbia. Patients are treated uniformly based on provincial policies and guidelines. Patients were divided into 63 Asian (3.6%) and 1,804 nonAsian (96.4%) patients by surname with Asian names checked by telephone contact. Three risk groups were defined based on pretreatment prostate specific antigen, biopsy Gleason score and clinical T staging. For the whole cohort and each risk group survival was estimated using the Kaplan-Meier method and comparisons were made between the Asian and nonAsian populations.
The mean age of Asian and nonAsian men was 71.5 and 71 years, respectively. Median prostate specific antigen was 11.4 and 10 ng/ml, respectively (p = 0.7). Median Gleason score was 7 for Asian patients and 6 for nonAsian patients (p = 0.002). There were twice the percentage of Asian patients with Gleason scores 8 or greater than nonAsian (26.5% vs 13.8%, p = 0.003). More Asian patients had stage 3 or 4 disease than nonAsian (44.8% vs 34.9%, p = 0.095). A greater proportion of Asian patients were classified as being at high risk than the nonAsian population (60.3% vs 47.6%, p = 0.04). For the entire cohort, and the low, intermediate and high risk groups there were no differences in time to first failure, or cause specific or overall survival for Asian vs nonAsian men.
A greater proportion of patients of Asian descent present with high risk prostate cancer than nonAsian patients, which could be due to intrinsic biological differences and/or differences in diagnostic patterns. Survival outcomes after radiotherapy are the same for the 2 populations.
我们比较了加拿大不列颠哥伦比亚省接受前列腺癌根治性放疗的亚裔患者与非亚裔患者的生存结果。
自1994年以来，我们省级机构对1872例接受前列腺癌根治性放疗的男性患者进行了前瞻性随访，该机构负责协调不列颠哥伦比亚省的癌症治疗。患者根据省级政策和指南接受统一治疗。通过姓氏将患者分为63例亚裔（3.6%）和1804例非亚裔（96.4%）患者，亚裔姓名通过电话联系进行核对。根据治疗前前列腺特异性抗原、活检Gleason评分和临床T分期定义了三个风险组。对于整个队列和每个风险组，使用Kaplan-Meier方法估计生存率，并对亚裔和非亚裔人群进行比较。
亚裔和非亚裔男性的平均年龄分别为71.5岁和71岁。前列腺特异性抗原中位数分别为11.4和10 ng/ml（p = 0.7）。亚裔患者的Gleason评分中位数为7分，非亚裔患者为6分（p = 0.002）。Gleason评分8分或更高的亚裔患者比例是非亚裔患者的两倍（26.5%对13.8%，p = 0.003）。亚裔患者中3期或4期疾病的比例高于非亚裔患者（44.8%对34.9%，p = 0.095）。与非亚裔人群相比，亚裔患者中被归类为高危的比例更高（60.3%对47.6%，p = 0.04）。对于整个队列以及低、中、高风险组，亚裔和非亚裔男性在首次失败时间、病因特异性生存率或总生存率方面没有差异。
与非亚裔患者相比，亚裔血统的患者中高危前列腺癌的比例更高，这可能是由于内在生物学差异和/或诊断模式的差异。两个群体放疗后的生存结果相同。
